{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T10:02:09Z","timestamp":1780999329847,"version":"3.54.1"},"reference-count":7,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pain Practice"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Gabapentin is one of the most frequently prescribed analgesic medications in the United States, commonly used for treating neuropathic pain conditions. While generally thought to have a favorable adverse effect profile, emerging data have implicated gabapentin in cases of respiratory depression and overdose\u2010deaths, especially when combined with opioids and other central nervous system depressants. As a result, a growing number of states have reclassified gabapentin as a Schedule\u2010V controlled substance. However, such regulations may risk varied unintended consequences, such as restricting access to a valuable nonopioid analgesic and potentially facilitating illicit market activity. As such, vulnerable populations, particularly those in rural and low\u2010income areas, may face increased barriers to care. This commentary evaluates the rationale for regulating gabapentin, examines the potential risks associated with such oversight, and suggests a way forward to reduce misuse while maintaining access to gabapentin for patients who genuinely need it.<\/jats:p>","DOI":"10.1111\/papr.70158","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T16:30:57Z","timestamp":1777566657000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Looming Concerns With Gabapentin Oversight: Balancing Safety and Access"],"prefix":"10.1111","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1028-8904","authenticated-orcid":false,"given":"Saba","family":"Javed","sequence":"first","affiliation":[{"name":"Department of Pain Medicine The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry C.","family":"Driver","sequence":"additional","affiliation":[{"name":"Department of Pain Medicine The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4300-1711","authenticated-orcid":false,"given":"Jay","family":"Karri","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery University of Maryland School of Medicine  Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"issue":"2","key":"e_1_2_14_2_1","first-page":"S89","article-title":"Gabapentinoid Pharmacology in the Context of Emerging Misuse Liability","volume":"61","author":"Evoy K. E.","year":"2021","journal-title":"Journal of Clinical Pharmacology"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7119a3"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S144963"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15352"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2017.11.113"},{"key":"e_1_2_14_7_1","article-title":"Effect of Restricting the Legal Supply of Prescription Opioids on Buying Through Online Illicit Marketplaces: Interrupted Time Series Analysis","volume":"361","author":"Martin J.","year":"2018","journal-title":"BMJ (Online)"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/amajethics.2020.743"}],"container-title":["Pain Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/papr.70158","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/papr.70158","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/papr.70158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T09:44:11Z","timestamp":1780998251000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/papr.70158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":7,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1111\/papr.70158"],"URL":"https:\/\/doi.org\/10.1111\/papr.70158","archive":["Portico"],"relation":{},"ISSN":["1530-7085","1533-2500"],"issn-type":[{"value":"1530-7085","type":"print"},{"value":"1533-2500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"2025-04-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70158"}}